secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYCOR MEDICAL INC (VYCO)
CIK:        0001424768
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001493152-25-023207
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vycor Medical Q3 revenue $514K (+31% YoY); posts GAAP operating profit of $32K
------------------------------------------------------------------------------

- Q3 2025 revenue $513,792, up 31% YoY; Vycor Medical division up 32% to $492K, mostly US growth.
- GAAP operating profit of $32,085 in Q3 vs. loss in prior year; non-GAAP operating profit $60,162.
- Nine-month revenue $1,446,523 (+28% YoY); non-GAAP operating profit $166,262 vs. $27,021 in 2024.
- Gross margin dipped to 88% (Q3) and 84% (9-month) from 90% due to validation costs and international mix.
- Three new peer-reviewed papers on VBAS published; NeuroEyeCoach study validates home-based therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1424768/000149315225023207/0001493152-25-023207-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1424768/000149315225023207/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-023207

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer